What’s the downside of easing treatment barriers for opioid use disorder? Elizabeth Tracey reports

What’s the downside of easing treatment barriers for opioid use disorder? Elizabeth Tracey reports

Imagine needing a daily dose of methadone to manage opioid use disorder and suddenly being told you can take it at home. Sounds convenient, right? But is it safe? In this thought-provoking episode from Johns Hopkins Medicine Podcasts, expert Eric Strain dives into the complexities of easing treatment barriers during the Covid-19 pandemic. With temporary federal guidelines allowing more flexible access to methadone and buprenorphine, the question arises: Are we trading convenience for safety?

Strain explores the potential pitfalls of this approach, particularly the risk of methadone diversion and misuse when taken outside a clinical setting. While these changes were necessary to reduce clinic visits during the pandemic, there's a growing debate about making them permanent. Strain emphasizes the need for careful monitoring and consideration of both the benefits and risks involved. This episode is a must-listen for anyone affected by or interested in substance use disorders.

Whether you're navigating your own recovery journey, supporting a loved one, or simply curious about addiction treatment, you'll find valuable insights here. Strain's balanced perspective sheds light on the ongoing challenges and the need for thoughtful policy decisions in addiction care. Tune in to gain a deeper understanding of how Covid-19 has reshaped opioid treatment and what it means for the future of addiction care.